The research aims to determine the impact of a syndromic mutiplex PCR assay (FilmArray) on the management of patients hospitalized in ICU for severe respiratory disease. During the SARS-CoV-2 outbreak, the diagnosis of pneumonia has become considerably more complex as the biological, radiological and clinical criteria of covid-19 interfere with the standard criteria for the diagnosis of severe respiratory diseases. Moreover, patients with COVID-19 are at higher risk of developing other associated infections and thus, patients have therefore often been treated with antibiotics, adequately or not, due to difficulty to quickly identify the etiology of their symptoms with conventional methods. In order to improve their treatment, both diagnostic and therapeutic, we set up a new syndromic molecular test in our laboratories to accelerate and improve the pneumonia management and antibiotic stewardship. This research will include 100 to 150 adult patients hospitalized in ICU during the first half of 2020. It will take place within the Nancy University Hospital and the Reims University Hospital, France.
Study Type
OBSERVATIONAL
Enrollment
150
Molecular test performed on respiratory samples realized for microbiological routine testing as part of the care
Therapeutic decision
Antibiotic prescription modification following the FilmArray results as: * No prescription * No change in antibiotic utilization * Antibiotic initiation * Antibiotic escalation * Antibiotic de-escalation * Antibiotic discontinuation
Time frame: 24 h following the FilmArray results
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.